FDA Approves Sevabertinib for First-Line HER2-Mutant NSCLC

The FDA has expanded accelerated approval of sevabertinib for first-line treatment of adults with HER2-mutant advanced non-small cell lung cancer.

The U.S. Food and Drug Administration (FDA) has expanded the accelerated approval of sevabertinib (Hyrnuo) to include adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors carry activating HER2 (ERBB2) tyrosine kinase domain (TKD) mutations.

The September 9, 2026 decision expands sevabertinib into the first-line treatment setting, meaning the targeted therapy can now be used in eligible patients who have not previously received systemic treatment for advanced disease. The FDA previously granted accelerated approval to sevabertinib in November 2025 for patients with HER2-mutant NSCLC who had already received systemic therapy.

The latest regulatory decision could represent an important development for patients with HER2-mutated NSCLC, a molecularly defined form of lung cancer that has historically had limited targeted treatment options.

What Is Sevabertinib?

Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) designed to target mutant HER2. HER2, also known as ERBB2, is a protein involved in signaling pathways that regulate cell growth and division.

Certain activating mutations in the HER2 gene can cause abnormal signaling that contributes to cancer development and progression. Sevabertinib works by inhibiting mutant HER2 signaling, potentially slowing or stopping the growth of cancer cells.

Importantly, the new FDA indication is specifically tied to HER2 TKD activating mutations. HER2 mutations are different from HER2 protein overexpression or gene amplification, so appropriate molecular testing is essential when determining whether a patient may be eligible for treatment.

FDA Approval Supported by SOHO-01 Trial Results

The expanded approval is based on results from the ongoing Phase 1/2 SOHO-01 trial (NCT05099172), which evaluated sevabertinib in patients with locally advanced or metastatic non-squamous NSCLC carrying HER2 TKD activating mutations.

In the treatment-naive cohort, 69 patients had not previously received systemic therapy for advanced disease. Sevabertinib produced an objective response rate (ORR) of 75%, with a 95% confidence interval of 64% to 85%.

Among patients who responded to treatment, 73% maintained their response for at least six months, while 38% maintained a response for at least 12 months. These findings provided the clinical basis for extending the accelerated approval into the first-line setting.

The earlier clinical development of sevabertinib also demonstrated activity in previously treated HER2-mutant NSCLC. Published SOHO-01 results reported responses across different patient cohorts, supporting continued investigation of the drug in HER2-mutated disease.

Why First-Line Treatment Matters

For patients with advanced NSCLC, identifying the molecular characteristics of a tumor can help guide treatment decisions. The expansion of sevabertinib into the first-line setting provides eligible patients with a targeted treatment option earlier in their treatment journey.

The importance of molecular testing is particularly relevant for HER2-mutant NSCLC because not every patient with HER2-positive or HER2-expressing disease will have the specific activating mutations required for sevabertinib treatment.

Comprehensive biomarker testing can therefore play an important role in identifying actionable mutations before treatment begins. The FDA's indication requires detection of the relevant HER2 TKD activating mutations using an FDA-authorized test.

Sevabertinib Dose and Safety Considerations

According to the current regulatory information reported for the expanded approval, the recommended dose of sevabertinib is 20 mg taken orally twice daily with food, continuing until disease progression or unacceptable toxicity.

Like other targeted cancer therapies, sevabertinib can cause adverse effects that require monitoring. The prescribing information includes warnings and precautions involving diarrhea, hepatotoxicity, interstitial lung disease or pneumonitis, left ventricular dysfunction, ocular toxicity, pancreatic enzyme elevation and embryo-fetal toxicity.

Patients receiving sevabertinib should discuss potential side effects and monitoring requirements with their oncology team. Treatment decisions should be individualized according to the patient's cancer characteristics, medical history and overall health.

Confirmatory Research Remains Important

The FDA's decision is an accelerated approval, rather than a traditional approval based on confirmation of clinical benefit.

Under the accelerated approval pathway, promising therapies can become available based on evidence using surrogate endpoints that are considered reasonably likely to predict clinical benefit. Continued approval can depend on confirmatory studies verifying and describing that benefit.

For sevabertinib, the ongoing Phase 3 SOHO-02 trial (NCT06452277) is evaluating sevabertinib against standard treatment in patients with advanced HER2-mutant NSCLC who have not previously received systemic therapy. The trial is designed to provide additional evidence about the drug's efficacy and safety in the first-line setting. ClinicalTrials.gov lists the study as a randomized Phase 3 trial with an estimated enrollment of 444 participants.

This distinction is important for patients and readers because accelerated approval does not mean that all questions about a medicine's long-term clinical benefit have been definitively answered.

A Growing Role for Precision Oncology

The sevabertinib decision reflects the broader movement toward precision oncology, in which cancer treatment is increasingly selected according to specific genetic changes within a tumor.

HER2-mutated NSCLC represents a relatively distinct molecular subgroup of lung cancer. Targeted therapies such as sevabertinib are being developed to address the biological mechanisms driving these cancers rather than relying solely on treatments selected according to cancer location or histology.

The clinical development program for sevabertinib also includes research beyond the first-line NSCLC setting. Bayer is studying the drug in additional HER2-mutated solid tumors, while international regulatory decisions are continuing to shape its availability in different patient populations.

What the FDA Decision Means for Patients

For eligible adults with locally advanced or metastatic non-squamous NSCLC carrying HER2 TKD activating mutations, the September 2026 FDA decision provides an additional targeted treatment option that can be considered from the first line of therapy.

The decision is particularly significant because patients no longer need to have received prior systemic treatment to fall within the expanded U.S. indication. However, eligibility depends on confirmation of the appropriate HER2 mutation, and treatment should be determined by a qualified oncology professional.

As research continues, the results of the SOHO-02 confirmatory trial will be important in establishing the longer-term clinical benefit of first-line sevabertinib.

Conclusion

The FDA's September 2026 expansion of accelerated approval for sevabertinib (Hyrnuo) marks a significant development in the treatment of HER2-mutant non-small cell lung cancer. Supported by a 75% objective response rate in the treatment-naive SOHO-01 cohort, the decision brings a targeted oral therapy into the first-line setting for eligible patients.

The approval also highlights the growing importance of comprehensive molecular testing in advanced lung cancer. As confirmatory research continues, sevabertinib could become an increasingly important option within the evolving treatment landscape for HER2-mutated NSCLC.

Source: U.S. Food and Drug Administration (FDA), September 9, 2026; ClinicalTrials.gov; Bayer; published clinical data from the SOHO-01 study.

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice, diagnosis or treatment guidance. FDA approvals, prescribing information and clinical trial findings can change. Patients with HER2-mutated NSCLC should consult a qualified oncologist or other healthcare professional for advice about testing and treatment options. This article does not recommend or endorse sevabertinib or any other cancer treatment.